142 related articles for article (PubMed ID: 15683857)
1. A prospective controlled crossover trial of a new presentation (10% vs. 5%) of a heat-treated intravenous immunoglobulin.
Matamoros N; De Gracia J; Hernández F; Pons J; Alvarez A; Jiménez V
Int Immunopharmacol; 2005 Mar; 5(3):619-26. PubMed ID: 15683857
[TBL] [Abstract][Full Text] [Related]
2. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
Debes A; Bauer M; Kremer S
Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
[TBL] [Abstract][Full Text] [Related]
4. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
[TBL] [Abstract][Full Text] [Related]
5. A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin.
Mondorf AW; Stephan W; Uthemann H; Schuppan D; Lissner R
Arzneimittelforschung; 1981; 31(11):1928-30. PubMed ID: 6797445
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a new intravenous immunoglobulin preparation in primary immunodeficient patients.
Ochs HD; Lee ML; Fischer SH; Kingdon HS; Wedgwood RJ
Clin Ther; 1987; 9(5):512-22. PubMed ID: 3117369
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of intravenous gammaglobulin for immunoglobulin G subclass and/or antibody deficiency in adults.
Abdou NI; Greenwell CA; Mehta R; Narra M; Hester JD; Halsey JF
Int Arch Allergy Immunol; 2009; 149(3):267-74. PubMed ID: 19218820
[TBL] [Abstract][Full Text] [Related]
8. Treatment with gammaglobulin preparation for intravenous use in children with humoral immunodeficiency: clinical and immunologic follow-up.
Galli E; Barbieri C; Cantani A; Solano A; Longhi MA; Businco L
Ann Allergy; 1990 Feb; 64(2 Pt 1):147-50. PubMed ID: 2106278
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of Intragam 10 NF, the next generation 10% liquid intravenous immunoglobulin, in patients with primary antibody deficiencies.
Bleasel K; Heddle R; Hissaria P; Stirling R; Stone C; Maher D
Intern Med J; 2012 Mar; 42(3):252-9. PubMed ID: 22212346
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura.
Bussel JB; Hanna K;
Am J Hematol; 2007 Mar; 82(3):192-8. PubMed ID: 17109385
[TBL] [Abstract][Full Text] [Related]
11. A prospective controlled crossover trial of a new heat-treated intravenous immunoglobulin.
Zuhrie SR; Webster AD; Davies R; Fay AC; Wallington TB
Clin Exp Immunol; 1995 Jan; 99(1):10-5. PubMed ID: 7813100
[TBL] [Abstract][Full Text] [Related]
12. Adverse reactions of intravenous immunoglobulin.
Al-Wahadneh AM; Khriesat IA; Kuda EH
Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the clinical efficacy and safety of an intramuscular and an intravenous immunoglobulin preparation for replacement therapy in idiopathic adult onset panhypogammaglobulinaemia.
Garbett ND; Currie DC; Cole PJ
Clin Exp Immunol; 1989 Apr; 76(1):1-7. PubMed ID: 2500273
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence and biochemical features of hepatitis B surface antigenemia in patients with HIV-1 infection in Lagos, Nigeria.
Iwalokun BA; Hodonu SO; Olaleye BM; Olabisi OA
Afr J Med Med Sci; 2006 Sep; 35(3):337-43. PubMed ID: 17312742
[TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.
Fazekas F; Lublin FD; Li D; Freedman MS; Hartung HP; Rieckmann P; Sørensen PS; Maas-Enriquez M; Sommerauer B; Hanna K; ;
Neurology; 2008 Jul; 71(4):265-71. PubMed ID: 18645164
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.
Saravanan S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
J Microbiol Immunol Infect; 2009 Apr; 42(2):122-8. PubMed ID: 19597643
[TBL] [Abstract][Full Text] [Related]
18. Adenosine deaminase activity in serum of patients with hepatitis -- a useful tool in monitoring clinical status.
Kaya S; Cetin ES; Aridogan BC; Arikan S; Demirci M
J Microbiol Immunol Infect; 2007 Aug; 40(4):288-92. PubMed ID: 17712462
[TBL] [Abstract][Full Text] [Related]
19. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
20. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
Gordon A; Hobbs DA; Bowden DS; Bailey MJ; Mitchell J; Francis AJ; Roberts SK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):275-80. PubMed ID: 16460486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
